Join HSANZ
A free education (CPD) program is available for members developed by MOGA and Medscape on New Treatment for Options for Cancer Associated Thrombosis
Click here for Postcard
Details here
Another publication by Karthik Nath in blood advances
Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma
Data on the prognostic impact of pretherapy 18F-fluorodeoxyglucose–positron emission tomography (FDG-PET) in follicular lymphoma (FL) is conflicting. The predictive utility of pretherapy total metabolic tumor volume (TMTV) and maximum standardized uptake value (SUVmax) on outcome appears to vary between regimens. Chemoimmunotherapies vary in the extent of T-cell depletion they induce. The role of intratumoral T cells on pretherapy FDG-PET parameters is undefined. We assessed pretherapy FDG-PET parameters and quantified intratumoral T cells by multiple methodologies. Low intratumoral T cells associated with approximately sixfold higher TMTV, and FL nodes from patients with high TMTV showed increased malignant B-cell infiltration and fewer clonally expanded intratumoral CD81 and CD41 T-follicular helper cells than those with low TMTV. However, fluorescently labeled glucose uptake was higher in CD41 and CD81 T cells than intratumoral B cells. In patients with FDG-PET performed prior to excisional biopsy, SUVmax within the subsequently excised node associated with T cells but not B cells. In summary, TMTV best reflects the malignant B-cell burden in FL, whereas intratumoral T cells influence SUVmax. This may contribute to the contradictory results between the prognostic role of different FDG-PET parameters, particularly between short- and long-term T-cell–depleting chemoimmunotherapeutic regimens. The impact of glucose uptake in intratumoral T cells should be considered when interpreting pretherapy FDG-PET in FL.
For the full paper click here
We are delighted to share another publication by Julian Lindsay, a Leukaemia Foundation /HSANZ PhD Scholarship recipient. Julian is studying at Peter MacCallum Cancer Centre (in conjunction with University of Melbourne and The Fred Hutchinson Cancer Research Center, Seattle, USA) and focusing on Preventing Infection in Haematological Malignancy and Bone Marrow Transplantation.
He has had a number of publications accepted and this is his most recent one:
NHMRC Centre for Blood Transplant and Cell Therapies Webinar 17 June 2021
The Centre for Blood Transplant and Cell Therapies (CBTCT) brings together the largest allogeneic stem cell transplant units in Australia with a focus on identifying transplant and cell therapy strategies to reduce graft versus host disease and improve patient and disease outcomes after transplant. In this webinar series, speakers will review major topics in stem cell transplantation and cell therapy, highlighting how key advances are addressing the current challenges in stem cell transplantation. The fifth webinar of the series features A/Prof John Koreth who is the Director of Translational Research in Stem Cell Transplantation at the Dana Faber Cancer Institute at the Harvard Medical School. In this talk, A/Prof Koreth will be outlining the role of regulatory T cells in haematopoietic stem cell transplantation and their potential as therapeutic tools.
Speaker:
Associate Professor John Koreth – Dana Faber Cancer Institute and Harvard Medical School
When: Thursday 17 June 2021, 8am
Link to webinar:
Link to CBTCT website for all webinar recordings:
Brochure
On behalf of HSANZ President Leanne Berkahn and Vice President Steven Lane, this note is being shared from THANZ.
Dear colleagues,
Amidst the community concerns regarding COVID and COVID vaccination, some of us have noted cases of thrombocytopenia following COVID vaccination. Although immune thrombocytopenia (ITP) has been described in the medical literature following mRNA vaccines (Pfizer), we are now accumulating local experience with this phenomenon after AstraZeneca vaccination.
We are now LIVE with an online HREC approved REDCap registry to collect de-identified data on the presentation and clinical outcome of cases that you believe may represent an immune thrombocytopenia (Vaccine Induced ITP) following any COVID vaccination (Pfizer, AstraZeneca, etc). Some of these cases may occur as a relapse in patients with a prior history of ITP. Many cases may be de novo. Some patients may even share features with VITT/TTS (Vaccine Induced Immune Thrombosis and Thrombocytopenia). We would like to collect information on any of these presentations.
Please do not hesitate to contact us directly
Phil Choi ; Robert Bird or via THANZ with any queries. The link below requires no special software, and can be accessed and answered from your mobile device. So far it has taken clinicians less than 5 minutes to complete! All contributions will be acknowledged in any publications ensuing.
https://smex12-5-en-ctp.trendmicro.com:443/wis/clicktime/v1/query?url=https%3a%2f%2fredcap.link%2fVIITP%5fAUS&umid=9dee37cb-4816-4faa-babd-b746a64f2e1e&auth=bb7c7bbf7acee6ae97e29073e34f3e8b1808c238-6849cb76fb7f27edfd6b1c21ac7928afb95f09f2
Dr Phil Choi (ACT) and Professor Robert Bird (Qld)
On behalf of the THANZ Vaccine Induced Immune Thrombocytopenia Working Group, and ISTH Platelet Immunology Subcommittee
Statement regarding the potential risk of thrombotic/bleeding events after COVID‐19 vaccination
Updated 24 May 2021 10:00 AM
Leanne Berkahn and Steven Lane, on behalf of the HSANZ Council.
The Haematology Society of Australia and New Zealand is aware of a number of case reports of Vaccine-induced Prothrombotic Immune Thrombocytopenia (VIPIT) following COVID-19 Vaccination. This is a dynamic topic and the clinical data are still emerging. HSANZ does not provide comment on specific cases, particularly without access to all of the information. However, we acknowledge that there is an important role in facilitating communication on this topic.
The following resources are available for clinicians and others seeking information on the topic. Note, these resources are linked for general interest and the content and recommendations are not specifically endorsed by HSANZ. Our webpage will be updated as more information/ resources come to hand.
The Thrombosis Society of Australia and New Zealand have released some local guidelines. The following link provides information about the diagnosis and management of VIPIT and also a link to the referral form for testing of suspected cases.
NHMRC Centre for Blood Transplant and Cell Therapies Webinar 24 May 2021
The Centre for Blood Transplant and Cell Therapies (CBTCT) brings together the largest allogeneic stem cell transplant units in Australia with a focus on identifying transplant and cell therapy strategies to reduce graft versus host disease and improve patient and disease outcomes after transplant. In this webinar series, investigators from the CBTCT will review major topics in stem cell transplantation and cell therapy, highlighting how the activities of the CBTCT are addressing current challenges in stem cell transplantation. The fourth webinar of the series features A/Prof Luca Vago, who is the Group Leader of the Unit of Immunogenetics, Leukaemia Genomics and Immunobiology at the Vita-Salute San Raffaele University in Milano. In his talk, A/Prof Vago will be outlining recent advances in the understanding of the mechanisms of post-HSCT relapse.
Associate Professor Luca Vago - San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milano
When: Monday 24 May 2021, 5pm AEST
Brochure for webinar
from Leanne Berkahn (President), Steven Lane (Vice President), on behalf of the HSANZ Council and Nada Hamad, HSANZ Member.
The Haematology Society of Australia and New Zealand is aware of a number of case reports of Vaccine-induced Prothrombotic Immune Thrombocytopenia (VIPIT) following AstraZeneca COVID-19 Vaccination. This is a rapidly evolving field and the clinical data are still emerging. HSANZ aims to facilitate dissemination of information as it becomes available.
The HSANZ will not comment on individual cases however, the following resources may be useful in supporting clinicians and patients. The content and recommendations are not specifically endorsed by HSANZ. Our webpage will be updated as more information/resources emerge.
2nd April 2021 TGA Media Release: Specific Clotting Condition reported after COVID-19 Vaccination 2nd April 2021 ATAGI media release: ATAGI statement on COVID-19 vaccination and a reported case of thrombosisCOVID-19 Advisory for Ontario Canada VIPIT Guidance
British Society of Haematology VIPIT Guidance
German Thrombosis and Haemostasis Society VIPIT Guidance
The Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) has released a statement on the testing of VIPIT in Australia and New Zealand. For the full statement please go to the HSANZ Members only site.
Date of preparation: 6 April, 2021
The Haematology Society of Australia and New Zealand is aware of a number of case reports of Vaccine-induced Prothrombotic Immune Thrombocytopenia (VIPIT) following COVID-19 Vaccination.
The following resources are available for clinicians and others seeking information on the topic. Note, these resources are linked for general interest and the content and recommendations are not specifically endorsed by HSANZ.
https://www.tga.gov.au/media-release/specific-clotting-condition-reported-after-covid-19-vaccination
The Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) has released a statement on the testing of VIPIT.
For the full statement please go to the HSANZ Members only site
The Kanematsu Research Award is made annually by the Kanematsu Fund in memory of its founder Fusajiro Kanematsu and his wife Sen. The award is made for a single medical research project in the area of haematological disorders.
All information is available on the RCPA website with more information here
Closing date: 30 June 2021
For any questions, contact Eve Propper
© 2023 Haematology Society of Australia & New Zealand All Rights Reserved.
Privacy Policy
